Streetbeat News

Products Services

NGNE

Neurogene Inc. (NASDAQ:NGNE) will present interim efficacy and safety data from its NGN-401 gene therapy trial for Rett syndrome at the CNS Annual Meeting. The presentation will include data from both low- and high-dose cohorts.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:32 am

GNRC

Generac has been selected by the Department of Energy to enter negotiations for a $50 million grant as part of the Grid Resilience and Innovation Partnership. This selection highlights Generac's role in enhancing grid resilience and innovation.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:31 am

RGNX

REGENXBIO Inc. (NASDAQ:RGNX) reported positive Phase II data for its gene therapy ABBV-RGX-314 for wet AMD, showing significant reduction in treatment burden and sustained visual acuity. The therapy, developed with AbbVie, could become a one-time treatment option for bilateral wet AMD.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:14 am

BYON

KIRK

Kirkland's has entered a strategic partnership with Beyond to become the exclusive brick-and-mortar operator and licensee for new 'neighborhood' Bed Bath & Beyond locations. This partnership will leverage Kirkland's expertise in store operations and its existing footprint to explore store conversion opportunities and new markets.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:12 am

CYN

Cyngn has completed the first paid deployment of its autonomous DriveMod Forklift, marking a significant step in its commercialization. The forklift, part of Cyngn's Enterprise Autonomy Suite, is designed for high precision and safety in dynamic environments. Cyngn plans to expand its deployment by 2025.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:11 am

MIRA

MIRA Pharmaceuticals reports that its oral ketamine analog, Ketamir-2, has shown greater efficacy than FDA-approved treatments Gabapentin and Pregabalin in preclinical models of neuropathic pain. The company is conducting further studies and plans to submit an IND application by the end of 2024, with Phase I trials in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:10 am

PYPD

PolyPid published a full dataset from its first Phase 3 study of D-PLEX100 in the International Journal of Surgery. The SHIELD I study, one of the largest in over a decade for SSI prevention in colorectal resection, showed potential benefits for high-risk patients. The ongoing SHIELD II study focuses on large surgical incisions, with results expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:08 am

ACXP

Acurx Pharmaceuticals presented a scientific poster at IDWeek 2024, highlighting ibezapolstat's potential benefits for C. difficile Infection (CDI). The company is advancing ibezapolstat into international Phase 3 trials and preparing regulatory submissions in the EU, UK, Japan, and Canada. The drug has FDA QIDP and Fast-Track Designation.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:06 am

TEM

Avacta Therapeutics has initiated a collaboration with Tempus AI to enhance its pre|CISION® platform by identifying full addressable patient populations for its clinical programs. Tempus will provide analytical support and computational biology expertise.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:05 am

SYTA

TMUS

Siyata Mobile has launched its SD7 Ultra series 5G mission-critical push-to-talk cellular radio handsets on T-Mobile's 5G network, aimed at enhancing communication for emergency services.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:04 am